VPH — Valeo Pharma Income Statement
0.000.00%
- CA$10.36m
- CA$71.03m
- CA$53.91m
- 29
- 71
- 18
- 33
Annual income statement for Valeo Pharma, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2019 October 31st | 2020 October 31st | C2021 October 31st | 2022 October 31st | 2023 October 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.58 | 7.47 | 13.6 | 27.7 | 53.9 |
Cost of Revenue | |||||
Gross Profit | 1.4 | 1.38 | 3.96 | 6.28 | 13.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 10.3 | 11.8 | 26.4 | 47.3 | 71.1 |
Operating Profit | -3.74 | -4.34 | -12.8 | -19.6 | -17.2 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.62 | -4.76 | -14.2 | -26.9 | -27.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.62 | -4.76 | -14.2 | -25.7 | -27.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.62 | -4.76 | -14.2 | -25.7 | -27.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.62 | -4.76 | -14.2 | -25.7 | -27.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.073 | -0.081 | -0.2 | -0.314 | -0.323 |